Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View

The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.

    Mark Vickery headshot

    Top Research Reports for February 28, 2017

    Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Visa (V) and Biogen (BIIB).

      Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

      Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

        Arpita Dutt headshot

        Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

        Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

          The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean

          The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean

            Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

            Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

              The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

              The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb

                Biogen (BIIB) Beats on Q4 Earnings; Misses Sales

                BIIB???s fourth quarter 2016 earnings were better-than expected. The company posted earnings of $5.04 per share while our consensus called for EPS of $4.97.

                  Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

                  Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.

                    Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY

                    How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?

                      Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

                      Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

                        Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug

                        Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.

                          The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway

                          The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway

                            Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

                            Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.

                              Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?

                              Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.

                                Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

                                We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.

                                  The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal

                                  The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal

                                    Biogen (BIIB) Presents Positive Phase III Data on Spinraza

                                    Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

                                      Arpita Dutt headshot

                                      Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

                                      Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

                                        Biogen Licenses Amunix's XTEN Technology for Factor IX Drug

                                        Biogen Inc. (BIIB) exercised its option to enter into an exclusive, global license agreement with Amunix Operating Inc. to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.

                                          Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

                                          Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.

                                            AbbVie's Humira and Imbruvica Drive Performance in 2016

                                            AbbVie Inc.'s (ABBV) share price is up 5.9% so far this year.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold

                                              Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.

                                                Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy

                                                Ionis (IONS) and Biogen (BIIB) announced that FDA has approved Spinraza under Priority Review for the treatment of spinal muscular atrophy.

                                                  Arpita Dutt headshot

                                                  Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug

                                                  Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.